This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.
GSK’s Shingrix (zoster vaccine recombinant, adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination, according to interim results from the company’s
However, sales of its shingles jab Shingrix increased by only 1% on a constant currency basis, although the drugmaker is expecting strong growth from the vaccine in the second half of
Shingrix. Walmsley pinned GSK’s growth prospects on the launch of its HIV pill Cabenuva, as well as a potential RSV vaccine, currently in phase 3 trials, and a new ... GSK is confident that sales of Shingrix will increase in the second half of the year,
Pfizer and Sanofi are planning to keep almost all of their increase at 5% or lower, 3 Axis added, with GSK also increasing their prices of two vaccines, Shingrix and Pediarix,
Looking at the fourth quarter numbers, pharma sales slumped 5% to £4.6bn, but there was an encouraging 18% gain for vaccines to £1.74bn thanks to strong growth for Shingrix,
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... Also bringing the forecast up is GSK’s
More from news
Approximately 9 fully matching, plus 23 partially matching documents found.
In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...